Trade CureVac N.V. - CVAC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.76 |
| Open | 2.74 |
| 1-Year Change | -8.05% |
| Day's Range | 2.69 - 2.78 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 2.76 | -0.09 | -3.16% | 2.85 | 2.85 | 2.67 |
| Mar 28, 2025 | 2.97 | -0.29 | -8.90% | 3.26 | 3.30 | 2.94 |
| Mar 27, 2025 | 2.77 | -0.11 | -3.82% | 2.88 | 2.88 | 2.76 |
| Mar 26, 2025 | 2.82 | -0.02 | -0.70% | 2.84 | 2.90 | 2.82 |
| Mar 25, 2025 | 2.90 | -0.09 | -3.01% | 2.99 | 3.02 | 2.89 |
| Mar 24, 2025 | 2.99 | 0.08 | 2.75% | 2.91 | 2.99 | 2.87 |
| Mar 21, 2025 | 2.88 | -0.07 | -2.37% | 2.95 | 2.95 | 2.81 |
| Mar 20, 2025 | 2.95 | -0.05 | -1.67% | 3.00 | 3.04 | 2.92 |
| Mar 19, 2025 | 3.02 | 0.01 | 0.33% | 3.01 | 3.08 | 2.98 |
| Mar 18, 2025 | 3.02 | 0.00 | 0.00% | 3.02 | 3.08 | 2.99 |
| Mar 17, 2025 | 3.04 | 0.02 | 0.66% | 3.02 | 3.08 | 3.00 |
| Mar 14, 2025 | 2.99 | -0.02 | -0.66% | 3.01 | 3.11 | 2.99 |
| Mar 13, 2025 | 3.01 | -0.04 | -1.31% | 3.05 | 3.14 | 3.00 |
| Mar 12, 2025 | 3.15 | 0.00 | 0.00% | 3.15 | 3.20 | 3.09 |
| Mar 11, 2025 | 3.13 | 0.22 | 7.56% | 2.91 | 3.18 | 2.83 |
| Mar 10, 2025 | 2.90 | -0.11 | -3.65% | 3.01 | 3.06 | 2.88 |
| Mar 7, 2025 | 3.03 | -0.07 | -2.26% | 3.10 | 3.16 | 3.02 |
| Mar 6, 2025 | 3.17 | 0.07 | 2.26% | 3.10 | 3.19 | 3.07 |
| Mar 5, 2025 | 3.13 | 0.14 | 4.68% | 2.99 | 3.16 | 2.99 |
| Mar 4, 2025 | 3.02 | 0.06 | 2.03% | 2.96 | 3.05 | 2.96 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CureVac N.V. Company profile
CureVac N.V. (CVAC) is a global clinical-stage biopharmaceutical company that develops medicines based on messenger ribonucleic acid (mRNA).
The company was founded in 2000 and is headquartered in Tübingen, Germany. It is listed on the NASDAQ stock exchange in August 2020 under the ticker symbol ‘CVAC.’
CureVac’s product portfolio is focused on oncology, infectious diseases and protein therapy. According to the company, its lead clinical programmes are CV8102 for the treatment of four types of solid tumours and CV7202 for potential vaccination against rabies.
The company has partnered with UK-based pharmaceutical firm GlaxoSmithKline (GSK) to develop second-generation mRNA vaccines for Covid-19 with the potential to address multiple emerging variants with one vaccine. CureVac’s first generation mRNA Covid-19 vaccine candidate CVnCoV is also under development.
CureVac N.V. and GSK are also developing an influenza vaccine together. Other vaccines currently under development are for yellow fever, respirational syncytial virus, rota, malaria and universal influenza.
According to the company’s prospectus, the company originally existed as CureVac AG. A Dutch private holding company CureVac B.V. was incorporated and CureVac AG was made a unit of the holding company. CureVac B.V. was then converted to a Dutch public company named CureVac N.V. The current chief executive of the company is Franz-Werner Haas.
According to the company’s price history, CVAC stock price hit an all-time high of $151.8 per share in December 2020. The company has not distributed dividends since going public.
You can follow the ups and downs of the CVAC share value at Capital.com. Always stay on top of the latest price developments with our live CVAC stock chart.
| Industry: | Biotechnology & Medical Research (NEC) |
Friedrich-Miescher-Str. 15
TUEBINGEN
BADEN-WUERTTEMBERG 72076
DE
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com